NCT07598396招募中2 期
A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 21
- 主要终点
- Proportion of participants who have achieved remission by Week 76
研究概览
简要总结
This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of SLE for ≥ 6 months as assessed using the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria at screening
排除标准
- •Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
- •Treatment with investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment and during the study
- •Major surgery requiring hospitalization during the 4 weeks prior to screening or during screening, or any planned surgery or procedure requiring hospitalization during the 12 weeks following study drug administration
- •Alcohol or substance abuse within the 12 months prior to screening
- •Active infection of any kind, excluding fungal infection of the nail beds
- •Any major episode of infection as defined by the protocol
- •History of serious recurrent or chronic infection
- •History of progressive multifocal leukoencephalopathy (PML)
- •Tuberculosis (TB) infection
- •History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years
- •Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within the 12 months prior to screening or during screening
- •Catastrophic or severe antiphospholipid syndrome within the 12 months prior to screening or during screening. Antiphospholipid syndrome adequately controlled by anticoagulant therapy for at least 2 months prior to screening is acceptable
- •High risk for clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions
- •Active severe or unstable lupus-associated neuropsychiatric disease or where, in the opinion of the investigator, it is likely to require treatment with protocol-disallowed therapies. Examples of neuropsychiatric SLE manifestations include, but are not limited to the following: meningitis, retinitis, cerebral vasculitis, myelopathy, demyelination syndromes, acute confusional state, psychosis, acute stroke or stroke syndrome, cranial neuropathy, status epilepticus or seizures, cerebellar ataxia, and mononeuritis multiplex
- •History of any non-SLE disease treated with oral, intravenous, or intramuscular corticosteroids for more than 14 days in total during the one year prior to Day 1
- •History of treatment with any T cell-engaging bispecific antibodies or CAR-T therapy within the past 2 years
- •Receipt of any live or attenuated vaccine in the 28 days prior to or during screening
研究组 & 干预措施
Mosunetuzumab
Experimental
Participants will receive mosunetuzumab by subcutaneous (SC) injection.
干预措施: Mosunetuzumab (Drug)
结局指标
主要结局
Proportion of participants who have achieved remission by Week 76
时间窗: Up to Week 76
Drug-Free Remission is defined as achieving both of the following: Absence of disease activity maintained for 6 months after completion of mosunetuzumab treatment, and; not receiving any SLE-directed therapy (except for antimalarials) during the 6 months. Doses of prednisone (or equivalent) ≤5 mg/day to treat secondary adrenal insufficiency are permitted.
次要结局
- Percentage of participants with anti-drug antibodies (ADAs)(Baseline up to 2.5 years)
- CD19+ absolute counts in blood(Up to 2.5 years)
- Change in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue(Baseline to Week 76)
- Change in Subject's Global Assessment of Disease Activity (SGA)(Baseline to Week 76)
- Proportion of participants who achieve Definition of Remission in SLE (DORIS) by Week 76(Up to Week 76)
- Proportion of participants who achieve Complete Renal Response (CRR) at Weeks 24, 52, 76, and 104(Weeks 24, 52, 76, and 104)
- Proportion of participants who achieve Partial Renal Response (PRR) at Weeks 24, 52, 76, and 104(Weeks 24, 52, 76, and 104)
- Percentage of participants with adverse events (AEs)(Up to 2.5 years)
- Longitudinal change in titers of anti-double-stranded (ds) DNA(Up to 2.5 years)
- Longitudinal changes in complement C3 and C4(Up to 2.5 years)
- Serum concentration of mosunetuzumab(Up to 2.5 years)
研究者
研究点 (21)
Loading locations...
相似试验
招募中
2 期
A Study to understand the Effectiveness, Safety, and what the body does to Mosunetuzumab in participants with Systemic Lupus Erythematosus with or without Active Lupus Nephritis2024-519930-22-00F. Hoffmann-La Roche AG5
招募中
2 期
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)Follicular lymphoma2022-500100-21-01Oslo University Hospital Hf80
招募中
2 期
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT07409181Boehringer Ingelheim405
招募中
2 期
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRDNCT07566364M.D. Anderson Cancer Center30
招募中
4 期
To evaluate effect of the polatuzumab vedotin in combination with four other drugs, rituximab (R), cyclophosphamide (C), doxorubicin (H), and prednisone (P) in Lymphoma that develops from mature B-cell of patientsCTRI/2025/04/085952Roche Products India Pvt Ltd48